Mike Quigley, Ph.D.

Mike Quigley, Ph.D.

Vice President

Head of Oncology Discovery Biology and Site Head, Redwood City


Mike serves as an Vice President, Head of Oncology Discovery Biology and Site Head, Redwood City at Bristol-Myers Squibb, leading a team of talented scientists focused on understanding biological mechanisms of I-O resistance. His team, recently established in Redwood City, California, is responsible for the identification, validation and preclinical development of potential therapies to target tumor- and host-mediated mechanisms of primary and adaptive resistance to immunotherapy. The translational insights generated by Mike’s team will ultimately inform the development of assets in the I-O pipeline, with the goal of delivering therapies that can activate antitumor activity in treatment-resistant patients.


Mike has spent his entire career focused on I-O drug discovery, both on the preclinical and translational sides. Prior to relocating to Redwood City, Mike worked at Bristol-Myers Squibb’s Lawrenceville site, where he led a team of scientists focused on I-O biology discovery. He has also worked in oncology discovery at MedImmune and Janssen. Mike received a Bachelor’s of Science in Marine Biology from Eckerd College, before earning his Ph.D. in Immunology at Duke University. Mike completed his post-doctoral studies at Dana-Farber Cancer Institute’s Department of Pediatric Oncology.  He is a member of the American Association of Immunologists (AAI) and the Society for Immunotherapy of Cancer (SITC). 

Interests and Expertise

Once an aspiring marine biologist, Mike was inspired to change paths following his mother’s death from metastatic melanoma. He often thinks about his mother, whose diagnosis came long before the advent of immunotherapy, while he’s working to identify new I-O mechanisms. For Mike, data showing the benefits of I-O treatment for some patients are about more than just numbers, they’re about patients like his mom. He’s driven to understand the complexities of cancer and I-O resistance so that more patients can have the potential to experience meaningful, long-term survival.


Mike is a familiar face in Redwood City, having joined the company in 2011 to work alongside I-O pioneers Nils Lonberg and Alan Korman. After a few years on the East Coast, Mike is excited to be back in California with his wife and two daughters, who share his love and appreciation for the wonders of nature.